Exploring Insmed's Key Growth Drivers...

It's been a banner year so far for Insmed Inc. (INSM), with its shares having more than doubled, thanks to Arikayce's surging sales, Brensocatib's ASPEN study success, and TPIP's promising phase II results.

from RTT - Top Story https://ift.tt/PDX9n4z
via IFTTT